Best Consumer Print Campaign

Share this article:
Bigger Than
Bigger Than

Rewards the best series of ads for a prescription drug, medical product or service appearing in any consumer magazine or newspaper.


• CDMiConnect and ­Genentech for “Romance” (Rituxan)

• Digitas Health and UCB for “Go Beyond Okay” (Vimpat)

• Draftfcb–NY and Thermo Fisher Scientific for “Know Where They Stand” (uKnow peanut test)

• GSW and Stryker for “Stryker GetAroundKnee Print Campaign”

• Healthwork Powered by BBDO & CDMi and Genentech for “Bigger Than” (Tamiflu)

Healthwork Powered by BBDO & CDMi and ­Genentech
Bigger Than

This campaign brilliantly illustrates the key insight that “There's no such thing as a little flu” by showing giant-sized flu sufferers dwarfing their household surroundings.

The play on proportion is arresting and powerful, and judges loved it.

“Great advertising that identifies with the consumer,” said one judge.

“A great use of humor,” a second judge noted.

The objective was to drive lasting brand equity for Tamiflu as a prescription flu treatment and prompt consumers to call a doctor as soon as symptoms occur.

“Nearly half of consumers don't know that there is a prescription solution for the flu and others wait so long to go to the doctor that it becomes too late to treat,” the agency explained. “For the Tamiflu ‘Bigger Than' campaign we targeted ‘Good Citizens,' consumers that are engaged, practical and pro-active. They are pro-active about today, tomorrow and the road ahead. In short, Good Citizens do the right thing.”

A third judge praised the campaign's “excellent alignment of visual and strategy.”

Results were outstanding. Genentech more than doubled the media buy given the campaign's initial success, and projected sales volume of Tamiflu for 2012 more than doubled.

CDMiConnect and ­Genentech

To illustrate how Genentech's Rituxan can help rheumatoid arthritis patients return to activities they love, the Romance effort shows them embracing representations of the activities.

Judges praised the campaign, which they said “steers clear of pharma-formulaic.”

BRC response has exceeded projections, and 71% of all responses are qualified.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.